Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Verteporfin

Catalog No: tcsc1950

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
129497-78-5

Formula:
$C_{41}H_{42}N_4O_8$

Pathway:
Stem Cell/Wnt;Autophagy

Target:
YAP;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : 8 mg/mL (11.13 mM; Need ultrasonic); H2O :

Alternative Names:
CL 318952

Observed Molecular Weight:
718.79

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Verteporfin is a benzoporphyrin derivative monoacid ring A, and can inhibit the activity of **YAP**.

In Vitro: Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI_{50}) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI_{50} for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 μM, 2.11 μM, and 5.61 μM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and paclitaxel (PTX) shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2].

In Vivo: Verteporfin (10 mg/kg, c.s.c.) and dasatinib significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen[1].